



DFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q74855

Yoshinori SEKIGUCHI, et al.

Appln. No.: 10/812,075

Group Art Unit: 1624

Confirmation No.: 3021

Examiner: Tamthom Ngo TRONG

Filed: March 30, 2004

For: NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE
DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE
THEREOF

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed after the later of three months from the application's filing date and the mailing date of the first Office Action on the

merits, but before a Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), and therefore Applicant is filing concurrently herewith a Statement Under 37 C.F.R. § 1.97(e). No fee under 37 C.F.R. § 1.17(p) is required.

The present Information Disclosure Statement is being filed thirty days or fewer from the communication from a foreign patent office and a Statement Under 37 C.F.R. § 1.704(d) is attached.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents, together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.


The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/812,075

Atty. Docket No. Q74855

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,


Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: May 4, 2007



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q74855

Yoshinori SEKIGUCHI, et al.

Appln. No.: 10/812,075

Group Art Unit: 1624

Confirmation No.: 3021

Examiner: Tamthom Ngo TRONG

Filed: March 30, 2004

For: NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE
DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE
THEREOF

STATEMENT UNDER 37 C.F.R. § 1.704(d)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and that the communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of said Information Disclosure Statement.

Respectfully submitted,

Susan J. Mack

Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: May 4, 2007



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q74855

Yoshinori SEKIGUCHI, et al.

Appln. No.: 10/812,075

Group Art Unit: 1624

Confirmation No.: 3021

Examiner: Tamthom Ngo TRONG

Filed: March 30, 2004

For: NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE
DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE
THEREOF

STATEMENT UNDER 37 C.F.R. § 1.97(e)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of said Information Disclosure Statement.

Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860


Susan J. Mack
Registration No. 30,951

WASHINGTON OFFICE

23373


CUSTOMER NUMBER

Date: May 4, 2007

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Complete if Known

Application Number	10/812,075
Confirmation Number	3021
Filing Date	March 30, 2004
First Named Inventor	Yoshinori SEKIGUCHI
Art Unit	1624
Examiner Name	Tamthom Ngo TRONG
Attorney Docket Number	Q74855

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	93/17017	A	09-02-1993	Janssen Pharmaceutica	
		WO	00/20358	A2	04-13-2000	Agouron Pharma	
		WO	01/96295	A	12-20-2001	Novartis Erfind Verwalt GmbH	
		WO	02/30890	A1	04-18-2002	Tanabe Seiyaku Co.	X
		WO	02/30891	A1	04-18-2002	Tanabe Seiyaku Co.	
		WO	03/035638	A	05-01-2003	Tanabe Seiyaku Co.	X
		WO	03/053933	A	07-03-2003	Hoffmann La Roche	
		WO	2004/004726	A	01-15-2004	Astrazeneca AB	
		EP	1 285 651	A1	02-26-2003	Takeda Chemical Industries Ltd.	
		WO	02/094799	A	11-28-2002	Neurogen Corp.	
		WO	02/058702	A	08-01-2002	Smithkline Beecham Corp.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		DAVID WUSTROW et al., "Aminopyrimidines with High Affinity for Both Serotonin and Dopamine Receptors", Journal of Medicinal Chemistry, Vol. 41, No. 5, 1998, pages 760-771	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.